Kyverna Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kyverna Therapeutics, Inc. (Nasdaq: KYTX) on February 24, 2026, reporting events occurring on February 23 and 24, 2026. The filing details significant changes to the Company's Board of Directors, including the appointment of two new directors and the resignation of one.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Appointment of Andrew Miller, Ph.D.: Appointed as a Class III director effective February 24, 2026. He joins the Science and Technology Committee and the Audit Committee. Dr. Miller previously founded Karuna Therapeutics (acquired by Bristol Myers Squibb in 2024) and currently chairs Progentos Therapeutics.
- Appointment of Sravan Emany: Appointed as a Class I director effective February 24, 2026. He will serve as Chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee. Mr. Emany is currently CFO of Beam Therapeutics and previously held senior roles at Ironwood Pharmaceuticals and Integra LifeSciences.
- Resignation of Daniel Spiegelman: Resigned from the Board and all committees effective February 24, 2026. The resignation is not due to any disagreement with the Company regarding operations, policies, or practices.
Compensation and Governance Details
Both new directors received compensation packages under the Company's Non-Employee Director Compensation Program, effective February 24, 2026:
- Cash Compensation:
- Dr. Miller: $40,000/year (Board), $10,000/year (Audit Committee), $7,500/year (Science and Technology Committee).
- Mr. Emany: $40,000/year (Board), $20,000/year (Audit Committee Chair), $5,000/year (Nominating and Corporate Governance Committee).
- Equity Grants:
- Both directors received stock options valued at $262,000, vesting monthly over 36 months.
- Both directors received Restricted Stock Units (RSUs) valued at $87,500, vesting annually over three years.
- Both awards include full acceleration upon a Change in Control.
Outlook and Risks
The filing does not provide updated business guidance, outlook, or specific risk factors beyond standard governance disclosures. The appointments suggest a strategic focus on strengthening oversight in science, technology, and financial governance.
Investor Verification Checklist
- Verify the impact of the new Audit Committee Chair (Mr. Emany) on financial reporting oversight.
- Review the Company's 2024 Equity Incentive Plan to understand the specific vesting terms and Change in Control definitions.
- Confirm the current composition of the Board following the resignation of Mr. Spiegelman and the addition of Dr. Miller and Mr. Emany.
- Check subsequent filings for any related-party transactions involving the new directors, though none were reported in this filing.